Mitchell Capital Management Co. boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 7.2% in the 4th quarter, Holdings Channel.com reports. The fund owned 10,717 shares of the company’s stock after purchasing an additional 723 shares during the period. Mitchell Capital Management Co.’s holdings in Johnson & Johnson were worth $1,687,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of the stock. SYM FINANCIAL Corp grew its position in shares of Johnson & Johnson by 3.7% during the 4th quarter. SYM FINANCIAL Corp now owns 1,729 shares of the company’s stock valued at $272,000 after purchasing an additional 62 shares in the last quarter. Gateway Advisory LLC boosted its stake in Johnson & Johnson by 2.1% during the fourth quarter. Gateway Advisory LLC now owns 3,054 shares of the company’s stock valued at $481,000 after buying an additional 63 shares during the period. Wealth Architects LLC grew its position in Johnson & Johnson by 1.5% during the third quarter. Wealth Architects LLC now owns 4,719 shares of the company’s stock worth $702,000 after buying an additional 70 shares in the last quarter. Westhampton Capital LLC increased its stake in Johnson & Johnson by 0.5% in the 3rd quarter. Westhampton Capital LLC now owns 13,255 shares of the company’s stock worth $1,973,000 after acquiring an additional 70 shares during the last quarter. Finally, Center for Financial Planning Inc. raised its holdings in shares of Johnson & Johnson by 0.6% in the 3rd quarter. Center for Financial Planning Inc. now owns 12,423 shares of the company’s stock valued at $1,850,000 after acquiring an additional 70 shares in the last quarter. 67.25% of the stock is currently owned by institutional investors and hedge funds.
Several research firms recently weighed in on JNJ. JPMorgan Chase & Co. upped their price objective on shares of Johnson & Johnson from $157.00 to $175.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 27th. Cantor Fitzgerald raised their price objective on shares of Johnson & Johnson from $180.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, January 26th. Raymond James raised their price target on Johnson & Johnson from $158.00 to $183.00 and gave the company an “outperform” rating in a research report on Wednesday, January 27th. Credit Suisse Group lifted their price target on Johnson & Johnson from $168.00 to $193.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 27th. Finally, Morgan Stanley increased their price objective on Johnson & Johnson from $178.00 to $187.00 and gave the company an “overweight” rating in a research report on Wednesday, January 27th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and twelve have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $177.13.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Monday, January 25th. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.82 by $0.04. The firm had revenue of $22.50 million for the quarter, compared to analysts’ expectations of $21.62 billion. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The business’s revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the business earned $1.88 earnings per share. Sell-side analysts expect that Johnson & Johnson will post 7.99 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 9th. Shareholders of record on Tuesday, February 23rd will be given a $1.01 dividend. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.50%. The ex-dividend date of this dividend is Monday, February 22nd. Johnson & Johnson’s payout ratio is 46.54%.
In other news, COO Michael E. Sneed sold 54,662 shares of the stock in a transaction dated Wednesday, December 9th. The shares were sold at an average price of $152.93, for a total transaction of $8,359,459.66. Following the completion of the sale, the chief operating officer now directly owns 110,741 shares in the company, valued at $16,935,621.13. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.27% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
See Also: Cost of Debt
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.